ALG 135041
Alternative Names: ALG-135041Latest Information Update: 16 Aug 2023
At a glance
- Originator Aligos Therapeutics
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Trans-activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 21 Jun 2023 Early research in Liver cancer in USA (unspecified route)
- 21 Jun 2023 Preclinical trials in Liver cancer in USA (unspecified route)
- 21 Jun 2023 Pharmacodynamics data from a preclinical study in Liver cancer presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)